News Coverage

Click to expand/collapse Sep 27, 2021
Click to open news item in new windowRafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical Trial of CPI-613® (devimistat) in Combination with Hydroxychloroquine in Patients with Relapsed Clear Cell Sarcoma Begins Enrollment at City of Hope in Duarte, Calif.

Click to expand/collapse Aug 26, 2021
Click to open news item in new windowPresident and CEO of Rafael Pharmaceuticals, Sanjeev Luther, to Present at the 11th Annual World Orphan Drug Congress USA 2021

Click to expand/collapse Aug 25, 2021
Click to open news item in new windowRafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Click to expand/collapse Jul 01, 2021
Click to open news item in new windowRafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Click to expand/collapse Jun 30, 2021
Click to open news item in new windowRafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) Congress

Click to expand/collapse Jun 29, 2021
Click to open news item in new windowFDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer

Click to expand/collapse May 26, 2021
Click to open news item in new windowRafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program

Click to expand/collapse Mar 30, 2021
Click to open news item in new windowRafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Click to expand/collapse Jan 19, 2021
Click to open news item in new windowRafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

Click to expand/collapse Jan 13, 2021
Click to open news item in new windowRafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

   1    2   3   4